INTERNATIONAL JOURNAL OF HEMATOLOGY
Scope & Guideline
Delivering Cutting-Edge Findings in Hematology
Introduction
Aims and Scopes
- Hematological Malignancies:
The journal extensively covers research on hematological malignancies such as leukemia, lymphoma, and myeloma, focusing on their pathophysiology, diagnosis, and treatment strategies. - Bone Marrow and Stem Cell Transplantation:
A significant portion of the research is dedicated to the methodologies and outcomes of bone marrow and stem cell transplantation, including allogeneic and autologous transplants. - Coagulation Disorders:
The journal addresses various coagulation disorders, including hemophilia and thrombocytopenia, examining both the clinical implications and therapeutic approaches. - Transfusion Medicine:
Research related to blood transfusion practices, including safety and efficacy, is a core area of focus, highlighting advancements in transfusion strategies. - Genetic and Molecular Pathology:
There is a significant emphasis on the genetic and molecular aspects of hematological diseases, including studies on mutations, gene expression, and their implications for treatment. - Innovative Therapies and Clinical Trials:
The journal highlights the latest innovations in therapy, including novel drug therapies, immunotherapies, and clinical trial outcomes that impact patient care. - Patient Outcomes and Quality of Life:
Research evaluating patient outcomes, quality of life, and psychosocial aspects of living with hematological disorders is increasingly featured, emphasizing holistic care.
Trending and Emerging
- Precision Medicine:
There is a marked increase in research focusing on precision medicine approaches in hematology, tailoring treatments based on genetic and molecular profiling of patients. - Immunotherapy Developments:
Studies on immunotherapy, particularly CAR-T cell therapies and bispecific antibodies, are trending, reflecting a significant shift towards utilizing the immune system to combat hematological malignancies. - Real-World Evidence and Outcomes Research:
Research that provides real-world evidence on treatment effectiveness and patient outcomes is gaining traction, emphasizing the need for practical insights beyond clinical trial settings. - Molecular and Genetic Insights:
Emerging themes include detailed molecular and genetic analyses of hematological disorders, contributing to better understanding of disease mechanisms and targeted therapies. - Management of COVID-19 in Hematology Patients:
Given the global pandemic, there is a growing interest in understanding the implications of COVID-19 on patients with hematological conditions, including treatment adaptations and outcomes. - Patient-Centric Care and Quality of Life:
Research focusing on patient-reported outcomes and quality of life measures is increasingly emphasized, reflecting a broader understanding of patient experiences and needs.
Declining or Waning
- Traditional Chemotherapy Approaches:
There is a noticeable decrease in publications focused solely on traditional chemotherapy regimens, as the field increasingly shifts towards targeted therapies and personalized medicine. - Basic Hematology Research:
Basic research in hematology, particularly studies that do not translate into clinical applications, appears to be waning as the emphasis moves towards translational and clinical research. - Longitudinal Studies of Established Treatments:
Longitudinal studies examining established treatment regimens without new intervention strategies have become less frequent, possibly due to a focus on novel therapies. - Epidemiological Studies:
The publication of epidemiological studies related to hematological conditions has declined, potentially reflecting a shift towards more clinical and therapeutic research. - Animal Models in Hematology Research:
Research utilizing animal models for hematological studies is less frequently published, as there is a growing preference for human-centric clinical research.
Similar Journals
Blood Research
Illuminating the Path in Blood Research and Patient CareBlood Research, published by SPRINGER, is a premier journal dedicated to the multifaceted realm of hematology, serving as a crucial platform for disseminating innovative research findings and advancements in the diagnosis and treatment of blood-related disorders. With an ISSN of 2287-979X and an E-ISSN of 2288-0011, this journal is recognized for its commitment to scholarly excellence and impact in the field, currently holding a reputable Q2 ranking in the Hematology category as per the 2023 metrics. The journal spans from 2013 to 2024, providing a broad archive of quality research that is vital for researchers, healthcare professionals, and students alike. Although it is not an Open Access journal, it offers insightful contributions that enhance the understanding of hematological science, fostering the exchange of knowledge crucial for advancing patient care and clinical practices globally. The journal’s performance is underscored by its Scopus ranking in the 46th percentile, reflecting its significant role in the ongoing discourse in hematology.
LEUKEMIA
Bridging Science and Practice in HematologyLEUKEMIA, published by SpringerNature, is a premier journal in the field of hematology and oncology, with ISSN 0887-6924 and E-ISSN 1476-5551. Established in 1987, this esteemed publication serves as a critical platform for disseminating groundbreaking research and comprehensive reviews on the pathophysiology, diagnosis, and treatment of leukemia and related hematological disorders. With a distinguished impact, it holds a top-tier status in several categories, including Q1 rankings in Anesthesiology and Pain Medicine, Cancer Research, Hematology, and Oncology for 2023. The journal is globally recognized for its rigorous peer-review process and is highly regarded among academia, evidenced by its impressive Scopus rankings—7th in Hematology and 24th in Oncology. Researchers, clinicians, and students alike will benefit from the rich content that this journal offers, making it an invaluable resource in the fight against leukemia. The main objective of LEUKEMIA is to advance knowledge and encourage further innovations within the field, ensuring that vital insights reach practitioners and researchers around the world.
CURRENT OPINION IN HEMATOLOGY
Transforming contemporary issues into clinical solutions.CURRENT OPINION IN HEMATOLOGY is a leading peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the latest advancements and insights in the field of hematology. With an impressive impact factor and ranked in the first quartile (Q1) of its category, this journal serves as a vital resource for researchers, clinicians, and students seeking to stay informed on contemporary issues and emerging trends in hematological research and treatment. Established in 1994, it showcases critical reviews, expert commentary, and systematic analyses across a broad spectrum of hematology topics, contributing significantly to clinical and experimental knowledge through its robust editorial standards. While offering traditional subscription access, CURRENT OPINION IN HEMATOLOGY remains committed to providing a platform that bridges the gap between fundamental research and clinical application, making it indispensable for professionals dedicated to advancing patient care and scientific understanding in hematology.
HemaSphere
Delivering cutting-edge insights to the hematology community.HemaSphere, published by WILEY, stands at the forefront of hematology research, offering a vital platform for the dissemination of cutting-edge findings in the field. Since its inception in 2017 and official transition to Open Access in 2018, the journal has positioned itself as a leading conduit for high-impact research, maintaining a prestigious Q1 quartile ranking in the Hematology category as of 2023. Addressed in the United States at 111 River St, Hoboken, NJ, HemaSphere aims to foster a global dialogue among researchers, clinicians, and students by providing unrestricted access to high-quality content that encompasses clinical and experimental advancements. With an array of engaging articles, reviews, and commentaries, HemaSphere contributes significantly to the advancement of hematology, ensuring that critical knowledge is readily accessible to enhance patient care and innovative research. To explore the latest developments and breakthroughs in this dynamic field, we invite scholars, professionals, and students to engage with HemaSphere and elevate their understanding of hematologic science.
BONE MARROW TRANSPLANTATION
Innovating Hematology: Pioneering Bone Marrow Research.BONE MARROW TRANSPLANTATION, published by SpringerNature, stands as a leading journal in the fields of Hematology and Transplantation, as evidenced by its recognition in the Q1 category for both disciplines according to 2023 rankings. With an impressive impact factor and notable Scopus rankings—7th out of 54 in Medicine Transplantation and 25th out of 137 in Medicine Hematology—this journal is instrumental for researchers and professionals dedicated to advancements in bone marrow transplantation practices and research. Established in 1986, the journal publishes original research, clinical studies, and reviews that push the boundaries of current knowledge, making it essential reading for those looking to stay abreast of the latest developments in the field. Although offering limited Open Access options, BONE MARROW TRANSPLANTATION reaches a broad audience and furthers a global dialogue on best practices and innovative approaches in transplantation medicine. Its address in London, UK positions it at the heart of international research collaboration, fostering connections among scientists, clinicians, and students alike.
HAEMATOLOGICA
Pioneering Research in Hematology for Tomorrow's AdvancementsHAEMATOLOGICA, published by FERRATA STORTI FOUNDATION, is a prestigious journal in the field of hematology, recognized for its high impact and contribution to advancing research in this critical area of medicine. With an impressive Q1 ranking in the 2023 category of Hematology and a notable Scopus rank of #12 out of 137, the journal serves as an essential platform for disseminating innovative studies, clinical trials, and comprehensive reviews from 1947 to 2024. Based in Italy, with a commitment to quality and academic integrity, HAEMATOLOGICA fosters collaboration among researchers, practitioners, and students interested in the latest developments and methodologies within hematological science. Although it does not offer open access, the journal ensures that valuable insights are accessible through institutional subscriptions, emphasizing its role in shaping the future of hematologic research.
Hematology
Innovative Insights: Shaping the Future of HematologyHematology is a distinguished open-access journal published by Taylor & Francis Ltd, dedicated to advancing research and knowledge in the field of hematology. Established in 1996, the journal has continually evolved to meet the needs of a growing community of researchers and practitioners, providing a vital platform for disseminating innovative findings and clinical insights. With its impact factor reflecting a robust commitment to quality scholarship, Hematology has achieved a respectable position in its category as evidenced by its Q3 ranking in the Hematology category and ranks #85 out of 137 in the Scopus index, which positions it in the 38th percentile among its peers. The journal’s open-access policy, initiated in 2019, further enhances its reach and accessibility, allowing a broad audience of professionals, researchers, and students to engage with high-quality research without barriers. By covering a wide range of topics related to blood disorders, treatment methodologies, and emerging therapies, Hematology stands as an essential resource for those dedicated to innovation in this critical area of healthcare.
Egyptian Journal of Haematology
Connecting Scholars to Transform Hematology PracticeThe Egyptian Journal of Haematology, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of hematology, particularly within the context of Egypt and the broader Middle Eastern region. This journal is dedicated to disseminating high-quality research that explores the latest advancements in blood disorders, hematologic malignancies, and transfusion medicine. With a focus on original research, case studies, and reviews, it aims to provide a comprehensive platform for hematologists, researchers, and healthcare professionals to enhance their understanding and management of hematological conditions. Although it is not an open-access journal, the rigorous peer-review process ensures that only the most impactful studies are published, contributing to the journal's reputation in the academic community. The Egyptian Journal of Haematology serves as an essential tool for advancing knowledge, improving clinical outcomes, and fostering collaboration among experts in the field.
Hematology-American Society of Hematology Education Program
Bridging Research and Practice in HematologyHematology-American Society of Hematology Education Program is a premier peer-reviewed journal dedicated to advancing the field of hematology through comprehensive educational content. Published by the American Society of Hematology, this journal plays a crucial role in disseminating knowledge to researchers, clinicians, and students in hematology and related disciplines. With an impressive Q1 status in the field, it ranks among the top journals at the forefront of hematological research, as evidenced by its 60th percentile ranking in Scopus' Medicine - Hematology category. Although it does not offer open access, the journal provides invaluable insights and educational resources from leading experts, focusing on the latest advancements, treatment protocols, and evolving understanding of blood disorders. Covering a wide range of topics, from basic research to clinical applications, this journal is essential for anyone seeking to deepen their expertise and stay informed on the latest developments in hematology. For further engagement, readers can access insightful articles published since 2001, ensuring a rich repository of knowledge for ongoing research and clinical excellence.
AMERICAN JOURNAL OF HEMATOLOGY
Transforming Research into Clinical BreakthroughsAmerican Journal of Hematology, published by Wiley, stands as a premier outlet for the dissemination of cutting-edge research in the field of hematology. With a commendable impact factor and ranked #9 out of 137 in the Scopus medicine category, this journal has established a robust presence since its inception in 1976. Operating in the Q1 quartile for hematology, it serves as a crucial resource for researchers, clinicians, and students dedicated to understanding blood disorders and advancing treatment methodologies. While the journal does not currently offer open access options, it remains highly regarded for its rigorous peer-review process and impactful contributions to the scientific community. With coverage extending into 2024, the American Journal of Hematology is committed to fostering innovation and collaboration within the hematological sciences.